Author Archive

ACTION ALERT: Anti-Supplement Bill Back From the Dead

https://anh-usa.org/durbin-strikes-back/

Durbin Strikes Back

By ANH-USAOn  
Durbin Strikes Back

After we defeated his anti-supplement bill in 2022, Senator Dick Durbin (D-IL) is trying to do the same thing again. Let’s make sure he doesn’t succeed. Action Alert!

THE TOPLINE

  • Sen. Durbin is planning to reintroduce his legislation to require mandatory product listing for dietary supplements.
  • This is an unnecessary regulation that will restrict consumer choices, putting us on a road to high-dose supplement restrictions with no basis in safety or public health.
  • It is another instance in which the FDA shows its loyalty to drug companies by slapping needless red tape on its competitors in the natural product industry.

It’s time, once again, to defend our supplement access in the face of an FDA / Big Pharma / Sen. Durbin onslaught. We’ve done it before, and we can do it again—but not without a powerful grassroots response telling Congress NOT to restrict our supplements.

MPL on the move

Earlier this week, Sen. Durbin, a longtime supplement opponent,  reportedly sent letters to several supplement industry trade groups indicating he would be reintroducing his Dietary Supplement Listing Act requiring mandatory product listing (MPL) for supplements. This comes on the heels of the FDA asking for the authority to require MPL in its list of legislative proposals for Fiscal Year 2025, as it did the previous year. With your help and support, we defeated Sen. Durbin’s legislation in 2022, and we can do so again.  But, like last time, we need your help.

MPL seeks to create a registry of all supplements on the market bringing it ever closer to the Canadian model that our colleagues at the Natural Health Products Protection Association have confirmed are wiping more and more products from Canadian retail shelves. Sen. Durbin and the FDA claim this policy would help regulators “know when new products are introduced and quickly identify dangerous or illegal products on the market.” We believe Sen. Durbin and the FDA are using safety as a smokescreen and that such a registry will be used to target and eliminate products that the agency believes do not comply with its ridiculous regulations. Just like in Canada.

Supplements: a health threat despite ZERO deaths?

For starters, this is a solution in search of a problem. The safety record for supplements is indisputable. Dietary supplements boast a consistent and remarkable safety profile making them many times more safe than conventional foods. Data from the American Association of Poison Control Center’s National Poison Data System (NPDS) typically show, year on year, that zero Americans die from taking dietary supplements.

Oft-cited reports on supplements causing adverse events fail to highlight that many cases are the result of unsupervised children swallowing pills, elderly Americans choking, and heart palpitations from ingesting too many diet pills, sexual enhancement pills, and energy drinks. Compare these numbers to the adverse events caused by pharmaceutical drugs, or even rates of food borne illness, and you’ll find that supplements are, overall, among the safest things you can consume.

The bottom line is that the supplement industry is not sickening and killing alarming rates of Americans to necessitate restrictive policies. So what’s the real motivation?

As we’ve argued through the years, the FDA takes an antagonistic attitude towards natural products because it relies on the drug industry for funding, and natural products compete with drugs. Put simply, the FDA is captured by drug industry interests. We believe this helps explain the motivation behind many anti-supplement policies, including the ridiculous limits the FDA imposes on what can be said about the benefits of supplements.

The case against MPL

The implications of MPL are even more concerning. MPL might be used to create a list of supplements that might lead to “adverse events,” similar to a legislative effort by Sen. Durbin we defeated a number of years ago. In that case, the list would be created by the FDA and the National Academies of Science, Engineering, and Medicine (NASEM)—the same body that once said people up to the age of 70 don’t need more than 600 IU of vitamin D per day, and above 4,000 IU may be dangerous. Through this and other mechanisms, such as harmonization with EU supplement levels we’ve discussed elsewhere, we can easily see how MPL could be used to eliminate access to high-dose supplements.

To make a long story short, mandatory listing legislation would add regulations to supplements that would increase prices for consumers and decrease available options, making it easy for the FDA to eliminate supplements that compete with the drugs that provide significant funding for the Agency. MPL would also throttle innovation in the supplement sector that delivers American consumers the most diverse array of cutting-edge products that support health, anywhere in the world.

Action Alert! Write to Congress and tell them to oppose mandatory product listing for supplements. Please send your message immediately.

(Go to top link to fill out form to your reps)

For more:

Category:

Activism, Supplements

A Protein Found in Human Sweat May Protect Against Lyme Disease

https://www.lymedisease.org/human-sweat-lyme-disease/

A protein found in human sweat may protect against Lyme disease

By Anne Trafton, MIT News

Lyme disease, a bacterial infection transmitted by ticks, affects nearly half a million people in the United States every year. In most cases, antibiotics effectively clear the infection, but for some patients, symptoms linger for months or years.

Researchers at MIT and the University of Helsinki have now discovered that human sweat contains a protein that can protect against Lyme disease. They also found that about one-third of the population carries a genetic variant of this protein that is associated with Lyme disease in genome-wide association studies.

It’s unknown exactly how the protein inhibits the growth of the bacteria that cause Lyme disease. However, the researchers hope to harness the protein’s protective abilities to create skin creams that could help prevent the disease, or to treat infections that don’t respond to antibiotics.

“This protein may provide some protection from Lyme disease, and we think there are real implications here for a preventative and possibly a therapeutic based on this protein,” says Michal Caspi Tal. She’s a principal research scientist in MIT’s Department of Biological Engineering and one of the senior authors of the new study.

Hanna Ollila, a senior researcher at the Institute for Molecular Medicine at the University of Helsinki and a researcher at the Broad Institute of MIT and Harvard, is also a senior author of the paper, which has been published in Nature Communications. The paper’s lead author is Satu Strausz, a postdoc at the Institute for Molecular Medicine at the University of Helsinki.

A surprising link

Lyme disease is most often caused by a bacterium called Borrelia burgdorferi. In the United States, this bacterium is spread by ticks that are carried by mice, deer, and other animals. Symptoms include fever, headache, fatigue, and a distinctive bull’s-eye rash.

Most patients receive doxycycline, an antibiotic that usually clears up the infection. In some patients, however, symptoms such as fatigue, memory problems, sleep disruption, and body aches can persist for months or years.

Tal and Ollila, who were postdocs together at Stanford University, began this study a few years ago in hopes of finding genetic markers of susceptibility to Lyme disease. To that end, they decided to run a genome-wide association study (GWAS) on a Finnish dataset that contains genome sequences for 410,000 people, along with detailed information on their medical histories.

This dataset includes about 7,000 people who had been diagnosed with Lyme disease, allowing the researchers to look for genetic variants that were more frequently found in people who had had Lyme disease, compared with those who hadn’t.

Secretoglobin

This analysis revealed three hits, including two found in immune molecules that had been previously linked with Lyme disease. However, their third hit was a complete surprise — a secretoglobin called SCGB1D2.

Secretoglobins are a family of proteins found in tissues that line the lungs and other organs, where they play a role in immune responses to infection. The researchers discovered that this particular secretoglobin is produced primarily by cells in the sweat glands.

To find out how this protein might influence Lyme disease, the researchers created normal and mutated versions of SCGB1D2 and exposed them to Borrelia burgdorferi grown in the lab.

They found that the normal version of the protein significantly inhibited the growth of Borrelia burgdorferi. However, when they exposed bacteria to the mutated version, twice as much protein was required to suppress bacterial growth.

The researchers then exposed bacteria to either the normal or mutated variant of SCGB1D2 and injected them into mice. Mice injected with the bacteria exposed to the mutant protein became infected with Lyme disease, but mice injected with bacteria exposed to the normal version of SCGB1D2 did not.

“In the paper we show they stayed healthy until day 10, but we followed the mice for over a month, and they never got infected. This wasn’t a delay, this was a full stop. That was really exciting,” Tal says.

Preventing infection

After the MIT and University of Helsinki researchers posted their initial findings on a preprint server, researchers in Estonia replicated the results of the genome-wide association study, using data from the Estonian Biobank. These data, from about 210,000 people, including 18,000 with Lyme disease, were later added to the final Nature Communications study.

The researchers aren’t sure yet how SCGB1D2 inhibits bacterial growth, or why the variant is less effective. However, they did find that the variant causes a shift from the amino acid proline to leucine, which may interfere with the formation of a helix found in the normal version.

They now plan to investigate whether applying the protein to the skin of mice, which do not naturally produce SCGB1D2, could prevent them from being infected by Borrelia burgdorferi. They also plan to explore the protein’s potential as a treatment for infections that don’t respond to antibiotics.

“We have fantastic antibiotics that work for 90 percent of people, but in the 40 years we’ve known about Lyme disease, we have not budged that,” Tal says. “Ten percent of people don’t recover after having antibiotics, and there’s no treatment for them.”

A new approach to Lyme prevention?

“This finding opens the door to a completely new approach to preventing Lyme disease in the first place, and it will be interesting to see if it could be useful for preventing other types of skin infections too,” says Kara Spiller, a professor of biomedical innovation in the School of Biomedical Engineering at Drexel University, who was not involved in the study.

The researchers note that people who have the protective version of SCGB1D2 can still develop Lyme disease, and they should not assume that they won’t. One factor that may play a role is whether the person happens to be sweating when they’re bitten by a tick carrying Borrelia burgdorferi.

SCGB1D2 is just one of 11 secretoglobin proteins produced by the human body. Tal also plans to study what some of those other secretoglobins may be doing in the body, especially in the lungs, where many of them are found.

“The thing I’m most excited about is this idea that secretoglobins might be a class of antimicrobial proteins that we haven’t thought about. As immunologists, we talk nonstop about immunoglobulins, but I had never heard of a secretoglobin before this popped up in our GWAS study. This is why it’s so fun for me now. I want to know what they all do,” she says.

The research was funded, in part, by Emily and Malcolm Fairbairn, the Instrumentarium Science Foundation, the Academy of Finland, the Finnish Medical Foundation, the Younger Family, and the Bay Area Lyme Foundation.

Click here to read the study.

SOURCE: Massachusetts Institute of Technology

_____________

**Comment**

These mice need to be observed for years, not 10 or even 30 days.

The most inaccurate statement in the article:

“We have fantastic antibiotics that work for 90 percent of people, but in the 40 years we’ve known about Lyme disease, we have not budged that,” Tal says. “Ten percent of people don’t recover after having antibiotics, and there’s no treatment for them.”

She’s right about not moving forward, but this 10% going onto suffer with chronic symptoms is flat-out wrong and needs to be corrected.  We also don’t have ‘fantastic antibiotics.’  We have a lot yet to learn about this complex illness due to a highly connected cabal with histories with biological weapons doing all the research utilizing faulty study designs.

For far too long this cabal has treated this as a mono-infection cured by a mono-therapy and nothing could be further from the truth.  There is absolutely nothing about this beast that is straight forward or easy, except the continued propaganda.

Category:

Lyme, research

Ivermectin Win: FDA Must Remove Controversial Verbiage From its Website While DOJ Attempts to Shut Down Pfizer Fraud Case

**UPDATE**

Besides bad-mouthing ivermectin, a U.S. government ‘cartel’ bribed large pharmacy chains like Walgreens and CVS with billions of dollars in contracts to promote COVID-19 vaccines and not fill prescriptions for ivermectin.  See:  The FDA’s War Against America’s Health

https://petermcculloughmd.substack.com/p/breaking-dr-mary-talley-bowden-reacts

Agency Capitulates by Removing False Claims on Ivermectin from Social Media and Internet

MAR 25, 2024

By Peter A. McCullough, MD, MPH

Thursday evening March 21, 2024, in an unprecedented court case, the US FDA led by  Commissioner Robert Califf, MD, a previously respected Duke Cardiologist, has settled a court case and taken down all of its false and misleading claims on ivermectin. The drug has been part of community standard of care for the treatment of COVID-19 with an excellent safety profile and signals of benefit in 101 studies.

During 2021, in what has been called “A War on Ivermectin” the US FDA engaged in false and misleading tweets and public messaging to dissuade doctors, pharmacists, and patients from using the drug in The McCullough Protocol and similar multi-drug regimens for acute COVID-19.  (See link for article and video)

According to an Epoch Times article , a court ordered the FDA to walk-back its negative posts about using ivermectin for COVID:

  • Studies show ivermectin works against COVID the FDA itself cites, but it’s webpage currently states it is not authorized or approved for use in preventing or treating COVID.
  • The court settlement requires the FDA to delete multiple social media posts that are strongly against ivermectin.
  • For doing this, doctors who sued the agency are dismissing their claims.
  • According to one of the doctors who sued, “This landmark case sets an important precedent in limiting FDA overreach into the doctor-patient relationship.”
  • Another ivermectin prescribing doctor who saw lives saved states that due to FDA interference, “we will never know how many lives were affected because patients were denied access to a lifesaving treatment because their doctor was ‘just following the FDA.’”
  • The three-judge panel of the U.S. Court of Appeals for the Fifth Circuit found that the law did not authorize the FDA to give medical advice.
  • Numerous doctors have chronicled the highly coordinated and timed actions between the FDA, CDC, AMA, APHA, and corporate controlled media to squash ivermectin – an extremely safe, cheap drug on the WHO’s essential list of medicines that has been used for decades without a prescription in many countries, including Africa which had essentially ZERO COVID due to the prolific use of the drug.

“FDA can inform, but it has identified no authority allowing it to recommend consumers ‘stop’ taking medicine,” U.S. Circuit Judge Don Willett, wrote for the court. The appeals court remanded the case back to the district court.

Predictably, the FDA didn’t get the memo:
  • and has not “admitted any violation of law or any wrongdoing, disagrees with the plaintiffs’ allegation that the agency exceeded its authority in issuing the statements challenged in the lawsuit, and stands by its authority to communicate with the public regarding the products it regulates.”
  • and has not changed its position that currently available clinical trial data do not demonstrate that ivermectin is effective against COVID-19. The agency has not authorized or approved ivermectin for use in preventing or treating COVID-19.”
Welcome to the Twilight Zone.

For a quick flashback, watch this video of a doctor being forcibly removed by police from a hospital board meeting simply for endorsing ivermectin that he used in his own private practice, and for evidently breaking protocol by whispering a “thanks” to a politician who questioned hospital policy. He shared at about 7:00 that doctors on staff at the hospital would come and see him to get ivermectin but would not speak their mind or prescribe it for fear of retribution from hospitals or their own medical groups. He states that 99% of doctors now have a contract with the hospital and are beholden to it, and that ‘brutal’ COVID treatment protocols, which one nurse blamed for 90% of hospital deaths, were followed to the letter due to government financial incentives.  Hospitals were simply not interested in early treatment which have saved lives and freed up hospital beds.

This video shows how the CARES Act signed into law in 2020 waived patient rights, and made hospitals rich (approx. 100K per COVID patient) due to these government incentives.

The ivermectin-prescribing doctor was unable to eat in the hospital employee lounge because he didn’t take the COVID shot.

And the reason the suit was brought in the first case was due to doctors suffering repercussions after prescribing ivermectin to patients with COVID.  Pharmacists refused to fill prescriptions.

The FDA is certainly guilty, as well as other government agencies.  But so are hospitals, medical groups like the AMA, APHA, ASHP, mainstream media, and doctors themselves.

Unless action is taken, this can and will happen again.

________________

https://www.naturalnews.com/2024-03-22-department-of-justice-intervenes-pfizer-fraud-case.

Collusion coverup: Department of Justice intervenes in Pfizer fraud case, in a corrupt attempt to shut the case down

03/22/2024  Lance D Johnson
Story at a glance: (summary by “Neo” LLM via Brighteon.AI)- The United States Department of Justice (DOJ) is attempting to shut down the Pfizer fraud case scheduled for April 17.- The lawsuit alleges that Pfizer-BioNTech violated the False Claims Act during their clinical trials and knowingly delivered a defective product to the world.- Former employee Brook Jackson, who worked at Ventavia Research Group (a company that conducted some of Pfizer’s COVID-19 vaccine clinical trials), is suing Pfizer, her former employer Ventavia, and another Pfizer contractor, ICON plc.- The DOJ asked the court to dismiss the lawsuit, claiming it would be inconsistent with their public health policy.- The DOJ’s motion to dismiss cites a flimsy hypothesis authored by the FDA, which supports the faulty vaccines and contradicts Jackson’s claims of fraud and negligence.  (See link for article)

Pfizer sunk to unbelievable lows to peddle their gene therapy shots including using children in ads
The shot not only flopped, it caused more COVID infections & an inflammatory syndrome

For more:

Category:

Activism, Cancer, Treatment, vaccines

Concurrent Infection of the Human Brain With Multiple Borrelia Species

https://www.mdpi.com/1422-0067/24/23/16906

Concurrent Infection of the Human Brain with Multiple Borrelia Species

by  1,*, 2,3, 1,3, 2,3, 4, 4, 5, 6, 6 and 1,*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2023, 24(23), 16906; https://doi.org/10.3390/ijms242316906
Submission received: 10 October 2023 / Revised: 22 November 2023 / Accepted: 26 November 2023 / Published: 29 November 2023
(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)

Abstract

Lyme disease (LD) spirochetes are well known to be able to disseminate into the tissues of infected hosts, including humans. The diverse strategies used by spirochetes to avoid the host immune system and persist in the host include active immune suppression, induction of immune tolerance, phase and antigenic variation, intracellular seclusion, changing of morphological and physiological state in varying environments, formation of biofilms and persistent forms, and, importantly, incursion into immune-privileged sites such as the brain. Invasion of immune-privileged sites allows the spirochetes to not only escape from the host immune system but can also reduce the efficacy of antibiotic therapy. Here we present a case of the detection of spirochetal DNA in multiple loci in a LD patient’s post-mortem brain. The presence of co-infection with Borrelia burgdorferi sensu stricto and Borrelia garinii in this LD patient’s brain was confirmed by PCR. Even though both spirochete species were simultaneously present in human brain tissue, the brain regions where the two species were detected were different and non-overlapping. The presence of atypical spirochete morphology was noted by immunohistochemistry of the brain samples. Atypical morphology was also found in the tissues of experimentally infected mice, which were used as a control.
For more:

‘The powers that be’ continue to ignore the issue of coinfection and concurrent infection.  This is a huge problem that partially explains why patients remain sick after the extremely unscientific and antiquated CDC Lyme treatment.

Category:

Lyme, research

WEF Planning to ‘Relaunch’ COVID ‘Pandemic’ Insider Warns

https://newsaddicts.com/wef-planning-relaunch-covid-pandemic-insider-warns/  Video Here (Approx. 9 Min)

WEF Planning to ‘Relaunch’ Covid Pandemic, Insider Warns

Hunter Fielding,

A bioweapons industry insider has blown the whistle to warn the public that the World Economic Forum (WEF) is planning to “relaunch” the Covid pandemic in order to finalize its “Great Reset” agenda.

According to Dr. Harvey Risch, a bioweapons expert and Yale University professor and epidemiologist, the “next pandemic” is about to erupt “seemingly out of nowhere.”

Risch warns that globalist elites are not finished with Covid yet, despite the appearance that the pandemic is “over.”

While the last pandemic may have failed to fully usher in the WEF’s “Great Reset,” another, more deadly Covid outbreak would surely complete the transition.

Both the “virus,” so-called, and the “vaccine,” so-called, were the perfect excuse for America’s bioweapons industry to boost itself as something the nation requires in order to serve the public good by protecting We the People against disease – or so it claims.

Dr. Risch is now alerting top trusted lawmakers in the hope of blocking the plans.  (See link for article and video)

_______________

**Comment**

Risch is not alone.  Seems it came stright from the horses mouth and Benzinga reported that WHO Director-General Tedros Ghebreyesus sounded the alarm that its a “matter of when not if” a new pandemic, infamously called ‘Disease X,’ will strike.  This sounds similar to billionaire Bill Gates’s recent public concerns that “we’re making the same mistakes again” by failing to adequately prepare.

But researchers are preparing by using breakthroughs in artificial intelligence (AI) to further speed up future vaccine development against Disease X. The Coalition for Epidemic Preparedness Innovations is providing up to $4.98 million to the Houston Methodist Research Institute to use AI to do just that. They aim to use AI to analyze the structures of potential viruses that may be the eventual Disease X and then identify specific parts of their proteins that cause an immune response. For now, their efforts focus on viruses such as Nipah and Lassa, but their goal is to get the time to develop a vaccine against a pandemic down to just 100 days.

Gee, what could go wrong?

Meanwhile, Politico reported that a growing dependence on artificial intelligence could pose a danger to the U.S. financial system, and regulators need to rethink their siloed approach to rule-making to minimize the risk, Securities and Exchange Commission Chair Gary Gensler said.

I’m sure trusting AI to create a ‘vaccine’ in 100 days to be put in human bodies is much safer, right?

Category:

Activism, vaccines, Viruses